FIGURE 2.

Dasatinib reversed the nintedanib-induced SRC activation (A) Cells were treated with dasatinib for 72 h and cell viability was analyzed with SRB assay (B) Cells were treated with 50 nM or 300 nM dasatinib, alone or in combination with 1 μM nintedanib for 24 h, and protein samples were analyzed by western blot. All experiments were performed in triplicates. Bars represent means ± SEM from three independent experiments.